Showing results (1-10 of 183) with videos related to
Sort By:
Pageof 19
Current Treatment Options in Oncology|December 22, 2007
Exploiting signal transduction pathways in acute myelogenous leukemiaAlexander E Perl, Martin CarrollBlood Advances|April 5, 2019
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemiaPamela J Sung, Mayumi Sugita, Holly Koblish, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2011
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapyAlexander E Perl, Margaret T Kasner, Doris Shank, et al.Hematology. American Society of Hematology. Education Program|December 10, 2017
The role of targeted therapy in the management of patients with AMLAlexander E PerlCurrent Opinion in Hematology|December 27, 2017
The most novel of the novel agents for acute myeloid leukemiaAlexander E PerlClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2019
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?Alexander E PerlBlood|November 14, 2024
Approaching a therapeutic inflection point for FLT3-mutated AMLAlexander E PerlBest Practice & Research. Clinical Haematology|March 25, 2021
Which novel agents will have a clinically meaningful impact in AML at diagnosis?Alexander E PerlBlood Advances|January 4, 2018
The role of targeted therapy in the management of patients with AMLAlexander E PerlPageof 19